- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04176133
Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination
A Randomized, Double-Blind, Placebo-Controlled, Single-Administration, Dose-Escalation Study of Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion:
- Men and women of age 65 years and older at the time of enrollment
- Eligible to receive Fluzone High-Dose
- Female subjects must be past menopause and not pregnant
- No history of anaphylactic reaction to gelatin, neomycin, or other vaccine component
- Must not have had the flu vaccine within the past 90 days
- Medically stable with no exacerbations or changes in medication regimen for chronic diseases in the past 3 months and no hospitalizations in the past 6 months
- Must be able to read/write English in order to provide informed consent and comply with study procedures
- Expected to be available for the duration of the study
Exclusion:
- Receipt of any other vaccines within the past 30 days prior to enrollment
- Acute illness within the last 7 days
- History of hypersensitivity to the flu vaccine or its components (including gelatin, formaldehyde, octoxinol, thimerosal, and chicken protein).
- History of Guillain Barré syndrome (GBS)
- History of bleeding disorders
- Medical contraindication to treatment with vaccine as indicated by a history of autoimmune disease, immune deficiency, or hypersensitivity to other vaccines.
- Unstable major cardiovascular, renal, endocrine, immunological or hepatic disorder
- Systolic blood pressure (SBP) < 110 mmHg or orthostatic hypotension [>20 mmHg fall in SBP or >10 mmHg fall in diastolic blood pressure (DBP) with standing] at the time of screening.
- Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) (within 14 days prior to entolimod administration). Note: Subjects with localized fungal infections of skin or nails are eligible.
- Clinical signs of febrile illness (temperature >99.5oF)
- Baseline vital signs with ≥Grade 2 abnormalities
Significant cardiovascular disease (e.g., myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism, venous thromboembolism) within 6 months prior to study drug administration; symptomatic dysrhythmias or unstable dysrhythmias requiring medical therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York Heart Association Class 3 or 4 congestive heart failure; or uncontrolled Grade ≥3 hypertension (diastolic blood pressure ≥100 mmHg or systolic blood pressure ≥160 mmHg) despite antihypertensive therapy.
o Significant screening ECG abnormalities, including unstable cardiac arrhythmia requiring medication, atrial fibrillation, 2nd-degree atrioventricular (AV) block type II, 3rd degree AV block, or Grade ≥2 bradycardia (within 14 days prior to entolimod administration).
Inadequate hepatic function (within 14 days prior to entolimod administration):
- Serum alanine aminotransferase (ALT) ≥3 × upper limit of normal (ULN) (Grade ≥1).
- Serum aspartate aminotransferase (AST) ≥3 × ULN (Grade ≥1)
- Serum alkaline phosphatase (ALP) ≥5 × ULN (Grade ≥2)
- Serum bilirubin ≥1.5 × ULN (Grade ≥1)
Positive antiviral serology:
- Positive hepatitis C virus (HCV) antibody or positive HCV ribonucleic acid (RNA) by quantitative PCR.
- Positive hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBc) antibody or undetectable hepatitis B (HBV) deoxyribonucleic acid (DNA) by quantitative polymerase chain reaction (PCR) testing.
- Positive human immunodeficiency virus (HIV) antibody.
- Use of medication that might interact with the flu vaccine including (but not limited to) specifically: aminopyrine, phenytoin sodium, theophylline, and warfarin sodium.
- Any ongoing treatment with immunosuppressive or immune-stimulant therapy
- Ongoing use of systemic corticosteroids.
- Blood or blood products given within the three months prior to vaccination and two months after vaccination
- Current and/or expected receipt of chemotherapy, radiation therapy or any other cytotoxic or immunosuppressive therapy [i.e. more than 10 mg of prednisone given daily or on alternative days for 2 weeks or more in the past 3 months]
- Receipt of another investigational pharmaceutical product within 60 days of treatment
- Diagnosis of Parkinson's Disease, previous stroke, or significant cognitive impairment (defined as MMSE <20)
- Other concerns that in the opinion of the PI would preclude a subject from participating in study procedures or from completing the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Entolimod 1 mcg
Subjects will receive entolimod as a single dose administered intramuscularly (1mcg)
|
Intramuscular (IM) single dose administration.
Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
Other Names:
Intramuscular (IM) single dose administration.
Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
Other Names:
|
Experimental: Entolimod 3 mcg
Subjects will receive entolimod as a single dose administered intramuscularly (3mcg)
|
Intramuscular (IM) single dose administration.
Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
Other Names:
Intramuscular (IM) single dose administration.
Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
Other Names:
|
Experimental: Entolimod 10 mcg
Subjects will receive entolimod as a single dose administered intramuscularly (10mcg)
|
Intramuscular (IM) single dose administration.
Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
Other Names:
Intramuscular (IM) single dose administration.
Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
Other Names:
|
Placebo Comparator: Placebo
Subjects will receive a placebo as a single dose administered intramuscularly (no study drug); placebo that looks exactly like the study drug, but contains no active ingredient.
|
Intramuscular (IM) single dose administration.
Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
Other Names:
Intramuscular (IM) single dose administration, no active ingredient.
A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Anti- A/H1N1 Antibody Titer
Time Frame: Baseline, 1 month
|
Change of the anti- A/H1N1 influenza virus strains serum circulating antibodies (as assessed using hemagglutination inhibition (HAI) assay) levels from baseline to 1 month.
|
Baseline, 1 month
|
Change in Anti-A/H3N2 Antibody Titer
Time Frame: Baseline, 1 month
|
Change of the anti-A/H3N2 influenza virus strains serum circulating antibodies (as assessed using hemagglutination inhibition (HAI) assay) levels from baseline to 1 month.
|
Baseline, 1 month
|
Change in Anti-B Antibody Titer
Time Frame: Baseline, 1 month
|
Change of the anti-B influenza virus strains serum circulating antibodies (as assessed using hemagglutination inhibition (HAI) assay) levels from baseline to 1 month..
|
Baseline, 1 month
|
Adverse Events
Time Frame: 1 year
|
The number of adverse events (AEs) related to dose limiting toxicities (DLTs); laboratory abnormalities; oxygen saturation and vital sign changes, and adverse electrocardiogram (ECG) findings for 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of Onset for Upper-respiratory Infections
Time Frame: 1 year
|
Subject self-reporting of the number of days to develop an upper-respiratory infection
|
1 year
|
Upper Respiratory Infections
Time Frame: 1 year
|
The total number of subjects to self-report an upper-respiratory infection
|
1 year
|
Change in Frailty
Time Frame: baseline, 2 months
|
Change in self-reported 5 items frail scale.
Frail scale scores range from 0-5, 1 point for each component, 0 = best 5 = worst (robust=0 points; pre-frail=0-1 points; frail 3-5 points)
|
baseline, 2 months
|
Change in 6-minute Walk Test
Time Frame: baseline, 2 months
|
Distance a subject is able to walk over 6 minutes over a hard flat surface
|
baseline, 2 months
|
Change in Grip Strength
Time Frame: baseline, 2 months
|
Measured by a grip dynamometer as reported in units of pounds.
|
baseline, 2 months
|
Change in Body Mass Index (BMI)
Time Frame: baseline, 2 months
|
Subject's BMI calculated as weight in kilograms divided by height in meters squared.
Uses measurements of height and weight obtained during study (with appropriate metric conversions)
|
baseline, 2 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Pignolo, MD, PhD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-004847
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Entolimod
-
BioLab 612 LLCCleveland BioLabs, Inc.UnknownColorectal CancerRussian Federation
-
Baylor College of MedicineCompleted
-
Roswell Park Cancer InstituteCleveland BioLabs, Inc.CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Cleveland BioLabs, Inc.WithdrawnMucositis | Tongue Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Squamous Cell Carcinoma of the Paranasal... and other conditions